{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:24:31Z","timestamp":1785237871715,"version":"3.55.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["187577"],"award-info":[{"award-number":["187577"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL166382"],"award-info":[{"award-number":["R01HL166382"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jtha.2024.04.006","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T02:22:10Z","timestamp":1713925330000},"page":"2103-2114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["RNA therapeutics to control fibrinolysis: review on applications in biology and medicine"],"prefix":"10.1016","volume":"22","author":[{"given":"Francesca","family":"Ferraresso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Kastrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.04.006_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0192623310389474","article-title":"Continuing education course #2: current understanding of hemostasis","volume":"39","author":"Gale","year":"2011","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.jtha.2024.04.006_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100081","article-title":"Fibrinolysis: an illustrated review","volume":"7","author":"Risman","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.006_bib3","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1111\/jth.12935","article-title":"Basic mechanisms and regulation of fibrinolysis","volume":"13","author":"Longstaff","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.006_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2024.04.006_bib5","first-page":"53","article-title":"The approach to a patient with a bleeding disorder: for the primary care physician","volume":"14","author":"Bashawri","year":"2007","journal-title":"J\u00a0Family Community Med"},{"key":"10.1016\/j.jtha.2024.04.006_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058009","article-title":"Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and \u03b5-aminocaproic acid -- a meta-analysis of randomised and observational trials of over 30.000 patients","volume":"8","author":"Meybohm","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2024.04.006_bib7","first-page":"CD008711","article-title":"Antifibrinolytic therapy to reduce haemoptysis from any cause","volume":"11","author":"Prutsky","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"10.1016\/j.jtha.2024.04.006_bib8","first-page":"30151","article-title":"The efficacy and safety of topical tranexamic acid: a systematic review and meta-analysis","volume":"S0887-7963","author":"Montroy","year":"2018","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jtha.2024.04.006_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jtha.2024.04.006_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10374","article-title":"RNA therapeutics in the clinic","volume":"8","author":"Curreri","year":"2023","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.jtha.2024.04.006_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2022.0054","article-title":"Drug metabolism and pharmacokinetics of antisense oligonucleotide therapeutics: typical profiles, evaluation approaches, and points to consider compared with small molecule drugs","volume":"33","author":"Takakusa","year":"2023","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jtha.2024.04.006_bib12","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s12276-023-00998-y","article-title":"Where should siRNAs go: applicable organs for siRNA drugs","volume":"55","author":"Ahn","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jtha.2024.04.006_bib13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/14760584.2022.2042257","article-title":"Clinical development and approval of COVID-19 vaccines","volume":"21","author":"Kalinke","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jtha.2024.04.006_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jtha.2024.04.006_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-1-4939-2074-7_23","article-title":"Measurement of blood coagulation factor synthesis in cultures of human hepatocytes","volume":"1250","author":"Heinz","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jtha.2024.04.006_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.jtha.2024.04.006_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtha.2024.04.006_bib18","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1073\/pnas.171251798","article-title":"Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems","volume":"98","author":"Caplen","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.04.006_bib19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2024.04.006_bib20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2024.04.006_bib21","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.jtha.2024.04.006_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A\u00a0review of patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1016\/j.jtha.2024.04.006_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2024.04.006_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2024.04.006_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jtha.2024.04.006_bib26","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2024.04.006_bib27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: state-of-the-art and future perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.jtha.2024.04.006_bib28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.jtha.2024.04.006_bib29","first-page":"2004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.04.006_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1304342","article-title":"Antisense oligonucleotides: a novel frontier in pharmacological strategy","volume":"14","author":"Collotta","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtha.2024.04.006_bib31","volume":"7","year":"1998","journal-title":"AIDS Treat News"},{"key":"10.1016\/j.jtha.2024.04.006_bib32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14348\/molcells.2023.2172","article-title":"Antisense oligonucleotide therapeutics for cystic fibrosis: recent developments and perspectives","volume":"46","author":"Kim","year":"2023","journal-title":"Mol Cells"},{"key":"10.1016\/j.jtha.2024.04.006_bib33","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse drug reactions and toxicity of the food and drug administration-approved antisense oligonucleotide drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jtha.2024.04.006_bib34","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.3390\/ijms24065944","article-title":"mRNA vaccines against SARS-CoV-2: advantages and caveats","volume":"24","author":"Echaide","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtha.2024.04.006_bib35","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1038\/s41467-022-32149-8","article-title":"Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses","volume":"13","author":"Pardi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2024.04.006_bib36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/infdis\/jix592","article-title":"Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease","volume":"217","author":"Meyer","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jtha.2024.04.006_bib37","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2024.04.006_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110514","article-title":"mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice","volume":"38","author":"Mu","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtha.2024.04.006_bib39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtha.2024.04.006_bib40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtha.2024.04.006_bib41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11095-022-03166-5","article-title":"Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size","volume":"39","author":"Di","year":"2022","journal-title":"Pharm Res"},{"key":"10.1016\/j.jtha.2024.04.006_bib42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/vaccines9020097","article-title":"An update on self-amplifying mRNA vaccine development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jtha.2024.04.006_bib43","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","article-title":"Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in\u00a0vivo delivery of saRNA","volume":"26","author":"Blakney","year":"2019","journal-title":"Gene Ther"},{"key":"10.1016\/j.jtha.2024.04.006_bib44","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/d41586-023-03859-w","article-title":"Self-copying RNA vaccine wins first full approval: what\u2019s next?","volume":"624","author":"Dolgin","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2024.04.006_bib45","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3390\/vaccines11071142","article-title":"Advances in saRNA vaccine research against emerging\/re-emerging viruses","volume":"11","author":"Liu","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jtha.2024.04.006_bib46","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-018-04252-2","article-title":"The CRISPR tool kit for genome editing and beyond","volume":"9","author":"Adli","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2024.04.006_bib47","first-page":"6","volume":"36","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2024.04.006_bib48","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.006_bib50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1631\/jzus.B2100196","article-title":"A\u00a0high-efficiency and versatile CRISPR\/Cas9-mediated HDR-based biallelic editing system","volume":"23","author":"Li","year":"2022","journal-title":"J\u00a0Zhejiang Univ Sci B"},{"key":"10.1016\/j.jtha.2024.04.006_bib51","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtha.2024.04.006_bib53","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of lentiglobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.006_bib54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12033-023-00724-z","article-title":"An update on the application of CRISPR technology in clinical practice","volume":"66","author":"Morshedzadeh","year":"2024","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.jtha.2024.04.006_bib55","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jtha.2024.04.006_bib56","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/pharmaceutics14020398","article-title":"Lipid nanoparticle delivery systems to enable mRNA-based therapeutics","volume":"14","author":"Semple","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jtha.2024.04.006_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for\u00a0vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jtha.2024.04.006_bib58","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1021\/acsnano.0c10064","article-title":"Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-containing lipid nanoparticles","volume":"15","author":"Sebastiani","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jtha.2024.04.006_bib59","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41467-022-35637-z","article-title":"Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis","volume":"14","author":"Han","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2024.04.006_bib60","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1021\/acs.molpharmaceut.2c00033","article-title":"Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells","volume":"19","author":"Ferraresso","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jtha.2024.04.006_bib61","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","article-title":"Lipid nanoparticle technology for therapeutic gene regulation in the liver","volume":"159","author":"Witzigmann","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jtha.2024.04.006_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.68","article-title":"Lipid nanoparticle delivery of siRNA to osteocytes leads to effective silencing of SOST and inhibition of sclerostin in\u00a0vivo","volume":"5","author":"Basha","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jtha.2024.04.006_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh0027","article-title":"Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A","volume":"16","author":"Strilchuk","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtha.2024.04.006_bib66","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.04.006_bib67","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtha.2024.04.006_bib68","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.jtha.2024.04.006_bib69","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtha.2024.04.006_bib70","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jtha.2024.04.006_bib71","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s40265-022-01788-y","article-title":"Valoctocogene roxaparvovec: first approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2024.04.006_bib72","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1160\/TH14-06-0505","article-title":"Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability","volume":"113","author":"Metzger","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.006_bib73","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MAT.0000000000001876","article-title":"Factor XII silencing using siRNA prevents thrombus formation in a rat model of extracorporeal life support","volume":"69","author":"Umei","year":"2023","journal-title":"ASAIO J"},{"key":"10.1016\/j.jtha.2024.04.006_bib74","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.thromres.2020.08.040","article-title":"Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function","volume":"196","author":"Liu","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.04.006_bib75","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.2843","article-title":"Inhibition of factor XI using a GalNAc-siRNA RBD5049: a novel antithrombotic drug with high potency and long duration","volume":"44","author":"Gan","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2024.04.006_bib76","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/ATVBAHA.117.308564","article-title":"Fibrinogen and fibrin in hemostasis and thrombosis","volume":"37","author":"Kattula","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.04.006_bib77","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.2021014559","article-title":"Suppression of fibrin(ogen)-driven pathologies in disease models through controlled knockdown by lipid nanoparticle delivery of siRNA","volume":"139","author":"Juang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.006_bib78","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.2021012537","article-title":"Hypofibrinogenemia with preserved hemostasis and protection from thrombosis in mice with an Fga truncation mutation","volume":"139","author":"Hur","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.006_bib79","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1111\/jth.15877","article-title":"Elimination of fibrin polymer formation or crosslinking, but not fibrinogen deficiency, is protective against diet-induced obesity and associated pathologies","volume":"20","author":"Hur","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.006_bib80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s44161-021-00006-4","article-title":"Aortic intimal resident macrophages are essential for maintenance of the non-thrombogenic intravascular state","volume":"1","author":"Hernandez","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jtha.2024.04.006_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/science.abl5450","article-title":"Fibrin is a critical regulator of neutrophil effector function at the oral mucosal barrier","volume":"374","author":"Silva","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jtha.2024.04.006_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.147208","article-title":"Effects of fibrinogen synthesis inhibition on vascular cognitive impairment during traumatic brain injury in mice","volume":"1751","author":"Muradashvili","year":"2021","journal-title":"Brain Res"},{"key":"10.1016\/j.jtha.2024.04.006_bib83","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1172\/JCI80313","article-title":"Fibrinolysis is essential for fracture repair and prevention of heterotopic ossification","volume":"125","author":"Yuasa","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.04.006_bib84","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.omtn.2020.03.015","article-title":"Treatment of hemophilia A using factor VIII messenger RNA lipid nanoparticles","volume":"20","author":"Chen","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jtha.2024.04.006_bib85","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.04.006_bib86","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.04.006_bib87","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/01.CIR.94.5.863","article-title":"Thrombin inhibitors in fibrinolysis","volume":"94","author":"Loscalzo","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.04.006_bib88","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1055\/s-0043-1768712","article-title":"Antithrombin deficiency is associated with prothrombotic plasma fibrin clot phenotype","volume":"123","author":"Natorska","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.006_bib89","first-page":"135","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B","volume":"9","author":"Machin","year":"2018","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2024.04.006_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100179","article-title":"Antithrombin lowering in hemophilia: a closer look at fitusiran","volume":"7","author":"Young","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.006_bib91","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-138692","article-title":"Targeting protein S using small interfering RNA is well tolerated and protects mice with hemophilia A from acute hemarthrosis","volume":"136","author":"Prince","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.006_bib92","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/jth.15025","article-title":"Anticoagulant protein S-New insights on interactions and functions","volume":"18","author":"Gierula","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.006_bib93","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1365-2516.2008.01825.x","article-title":"Plasminogen deficiency","volume":"14","author":"Mehta","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.006_bib94","doi-asserted-by":"crossref","first-page":"E9687","DOI":"10.1073\/pnas.1811172115","article-title":"Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease","volume":"115","author":"Baker","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.04.006_bib95","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood.V98.6.1662","article-title":"Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family","volume":"98","author":"Fujikawa","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.006_bib96","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1182\/blood.2020004976","article-title":"Sustained depletion of FXIII-A by inducing acquired FXIII-B deficiency","volume":"136","author":"Strilchuk","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.006_bib97","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/bloodadvances.2017011890","article-title":"Factor XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous thrombus size in mice","volume":"2","author":"Kattula","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.04.006_bib98","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1172\/JCI75386","article-title":"Factor XIII activity mediates red blood cell retention in venous thrombi","volume":"124","author":"Aleman","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.04.006_bib99","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.blre.2009.04.001","article-title":"Platelet\u00a0alpha-granules: basic biology and clinical correlates","volume":"23","author":"Blair","year":"2009","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2024.04.006_bib100","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi0508","article-title":"Genetically engineered transfusable platelets using mRNA lipid nanoparticles","volume":"9","author":"Leung","year":"2023","journal-title":"Sci Adv"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624002241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624002241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:10:46Z","timestamp":1762549846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624002241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":96,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1538783624002241"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.04.006","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA therapeutics to control fibrinolysis: review on applications in biology and medicine","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}